These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31407530)

  • 41. Assessment of ovarian reserve and reproductive outcomes in
    Ponce J; Fernandez-Gonzalez S; Calvo I; Climent M; Peñafiel J; Feliubadaló L; Teulé A; Lázaro C; Brunet JM; Candás-Estébanez B; Durán Retamal M
    Int J Gynecol Cancer; 2020 Jan; 30(1):83-88. PubMed ID: 31780568
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence and Penetrance of BRCA1 and BRCA2 Germline Mutations in Colombian Breast Cancer Patients.
    Torres D; Bermejo JL; Rashid MU; Briceño I; Gil F; Beltran A; Ariza V; Hamann U
    Sci Rep; 2017 Jul; 7(1):4713. PubMed ID: 28680148
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations.
    Ditchi Y; Broudin C; El Dakdouki Y; Muller M; Lavaud P; Caron O; Lejri D; Baynes C; Mathieu MC; Salleron J; Benusiglio PR
    Breast J; 2019 Jan; 25(1):16-19. PubMed ID: 30414230
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
    Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT
    Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers.
    Evans DG; Harkness EF; Howel S; Woodward ER; Howell A; Lalloo F
    Breast Cancer Res Treat; 2018 Feb; 167(3):779-785. PubMed ID: 29116468
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
    Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
    Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.
    van den Broek AJ; van 't Veer LJ; Hooning MJ; Cornelissen S; Broeks A; Rutgers EJ; Smit VT; Cornelisse CJ; van Beek M; Janssen-Heijnen ML; Seynaeve C; Westenend PJ; Jobsen JJ; Siesling S; Tollenaar RA; van Leeuwen FE; Schmidt MK
    J Clin Oncol; 2016 Feb; 34(5):409-18. PubMed ID: 26700119
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
    Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.
    Eisen A; Lubinski J; Klijn J; Moller P; Lynch HT; Offit K; Weber B; Rebbeck T; Neuhausen SL; Ghadirian P; Foulkes WD; Gershoni-Baruch R; Friedman E; Rennert G; Wagner T; Isaacs C; Kim-Sing C; Ainsworth P; Sun P; Narod SA
    J Clin Oncol; 2005 Oct; 23(30):7491-6. PubMed ID: 16234515
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
    Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E
    Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction.
    Stjepanovic N; Villacampa G; Nead KT; Torres-Esquius S; Melis GG; Nathanson KL; Teule A; Brunet J; Y Cajal TR; Llort G; Dienstmann R; Rue M; Domchek SM; Balmaña J
    Eur J Cancer; 2020 Jun; 132():53-60. PubMed ID: 32325420
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy.
    Pearson EJ; Nair A; Daoud Y; Blum JL
    Breast Cancer Res Treat; 2017 Feb; 162(1):59-67. PubMed ID: 28066861
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early onset breast cancer in Ashkenazi women carriers of founder BRCA1/2 mutations: beyond 10 years of follow-up.
    Dagan E; Gershoni-Baruch R; Kurolap A; Fried G
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27726213
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?
    Semple J; Metcalfe KA; Lubinski J; Huzarski T; Gronwald J; Armel S; Lynch HT; Karlan B; Foulkes W; Singer CF; Neuhausen SL; Eng C; Iqbal J; Narod SA;
    Breast Cancer Res Treat; 2015 Nov; 154(1):163-9. PubMed ID: 26467043
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
    Giannakeas V; Lubinski J; Gronwald J; Moller P; Armel S; Lynch HT; Foulkes WD; Kim-Sing C; Singer C; Neuhausen SL; Friedman E; Tung N; Senter L; Sun P; Narod SA
    Breast Cancer Res Treat; 2014 Aug; 147(1):113-8. PubMed ID: 25082516
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in BRCA1/2 Mutation Carriers.
    Vos JR; Oosterwijk JC; Aalfs CM; Rookus MA; Adank MA; van der Hout AH; van Asperen CJ; Gómez Garcia EB; Mensenkamp AR; Jager A; Ausems MG; Mourits MJ; de Bock GH;
    Cancer Epidemiol Biomarkers Prev; 2016 Aug; 25(8):1251-8. PubMed ID: 27277847
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
    Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
    Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
    Shimada S; Yoshida R; Nakashima E; Kitagawa D; Gomi N; Horii R; Takeuchi S; Ashihara Y; Kita M; Akiyama F; Ohno S; Saito M; Arai M
    Breast Cancer; 2019 Nov; 26(6):846-851. PubMed ID: 30980249
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
    Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G
    BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?
    Evans DG; Howell A
    Breast Cancer Res; 2004; 6(1):E7. PubMed ID: 14680492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.